Biovendor Group presents its CLIA, NGS, Microblot Array, microRNA and LAMP Product Lines at MEDICA 2021
By LabMedica International staff writers Posted on 15 Nov 2021 |
Image: KleeYa fully automated analyzer (Photo courtesy of BioVendor)
BioVendor Group (Brno, Czech Republic) presented its CLIA, NGS, Microblot Array, microRNA and LAMP product lines at the 2021 edition of MEDICA, the world's largest trade fair for medical technology, held from 15 to 18 November in Düsseldorf, Germany.
BioVendor presented its newly-launched KleeYab fully automated analyzer, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.
BioVendor demonstrated its new Next Generation Sequencing (NGS) technology, fastGEN designed for examination of the mutation status of oncomarkers in samples. Its technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material.
At MEDICA 2021, BioVendor also demonstrated its Microblot-Array (MBA), a new generation of a market-unique immunoblot array in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which is time and cost-saving. The technology eliminates the limited capacity of traditional BLOT strips and opens the way to high throughput testing. Simple processing can be done manually or automatically using any open ELISA analyzers. Additionally, BioVendor presented its complete solution for microRNAs (miRNAs) and other short non-coding RNA sequences (sncRNA) projects, starting with isolation, followed by screening for proper targets and their final quantification. BioVendor also showcased its loop-mediated isothermal amplification (LAMP) assays which bring a novel approach for direct detection of target nucleic acids without the need of isolation step. The unique architecture of the LAMP method ensures its high sensitivity and specificity, and a tolerance for inhibitory substances.
Related Links:
BioVendor Group
BioVendor presented its newly-launched KleeYab fully automated analyzer, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.
BioVendor demonstrated its new Next Generation Sequencing (NGS) technology, fastGEN designed for examination of the mutation status of oncomarkers in samples. Its technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material.
At MEDICA 2021, BioVendor also demonstrated its Microblot-Array (MBA), a new generation of a market-unique immunoblot array in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which is time and cost-saving. The technology eliminates the limited capacity of traditional BLOT strips and opens the way to high throughput testing. Simple processing can be done manually or automatically using any open ELISA analyzers. Additionally, BioVendor presented its complete solution for microRNAs (miRNAs) and other short non-coding RNA sequences (sncRNA) projects, starting with isolation, followed by screening for proper targets and their final quantification. BioVendor also showcased its loop-mediated isothermal amplification (LAMP) assays which bring a novel approach for direct detection of target nucleic acids without the need of isolation step. The unique architecture of the LAMP method ensures its high sensitivity and specificity, and a tolerance for inhibitory substances.
Related Links:
BioVendor Group
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear